Diagnosis and Management of Rifampicin-Induced Hemolytic Anemia

Clinical Presentation and Diagnosis

The American Thoracic Society recommends that hemolytic anemia is a rare but serious adverse effect of rifampicin, typically occurring with intermittent therapy or after reintroduction of the drug following a medication-free interval, with clinical presentation including acute onset of anemia with fatigue, pallor, and dyspnea, jaundice and dark urine due to hemoglobinuria, and elevated reticulocyte count 2
Laboratory findings for rifampicin-induced hemolytic anemia include elevated indirect bilirubin and reticulocyte count 2

The American College of Chest Physicians recommends immediate discontinuation of rifampicin upon suspicion of hemolytic anemia, and substitution with an alternative anti-TB medication while maintaining effective TB treatment 1
The American Thoracic Society suggests that rifabutin can be considered as an alternative rifamycin if the patient has not demonstrated cross-reactivity, with a typical dose of 150-300 mg daily 4
The Centers for Disease Control and Prevention recommend extending treatment duration to 18 months using a regimen without rifamycins, which may include isoniazid, ethambutol, pyrazinamide, and a fluoroquinolone 1, 6

The American Thoracic Society recommends monitoring liver function tests regularly, as other anti-TB medications can also cause hepatotoxicity 2, 8
The Centers for Disease Control and Prevention suggest documenting rifampicin allergy prominently in the patient's medical records and providing the patient with medical alert information regarding rifampicin allergy 6
The World Health Organization recommends avoiding intermittent rifampicin therapy, which is associated with higher risk of immune-mediated reactions 1